Skip to content
Parakho

Health X Platform Ltd

NSE HEALTHXBSE 533259healthxplatform.com

Q1 FY27, unaudited

Interest earned
₹0.08 Cr
Profit after tax
₹-0.51 Cr

As filed with the exchange, standalone basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, standalone basis
₹ croreQ1 FY27vs a year agoFY26
Interest earned0.08−17.27%0.38
Other income0.01−94.98%0.38
Total income0.09−73.72%0.76
Employee benefit expense0.08+11.02%0.30
Provisions & contingencies———
Profit before tax-0.51−369.68%-0.95
Tax expense0.00—0.00
Profit after tax-0.51−369.68%-0.95
Total comprehensive income-0.51−346.82%-0.94
Earnings per share
Earnings per share, basic₹-0.16₹-0.30
Earnings per share, diluted₹-0.16₹-0.30

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — from the company’s filing with NSE. Source

Earnings call

Q4 FY26

Health X Platform (formerly Sastasundar Ventures) reported Q4 FY26 revenue of Rs 356 crore, up 22% year-on-year, with EBITDA losses narrowing to Rs 20 crore from Rs 29 crore a year earlier. For the full year, revenue reached Rs 1,283 crore with EBITDA losses reduced to Rs 65 crore and a near breakeven PAT loss of Rs 1.4 crore. Management also discussed the launch of the JITO generic medicine brand, capacity expansion plans, and a proposed demerger of the finance division into a separately listed entity called Microsec Resources.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary

Filings

12 shown · 34 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Page generated from filings held to 25 Aug 2026.